Date: 2014-05-06
Type of information: R&D agreement
Compound: antibodies for targets selected by Synthon
Company: Synthon (The Netherlands) MAB Discovery (Germany)
Therapeutic area: Technology - Services
Type agreement: R&D licensing
Action mechanism:
Disease:
Details: * On May 6, 2014, Synthon Biopharmaceuticals and MAB Discovery have announced the execution of a research and license agreement. Under the terms of the agreement, MAB Discovery will generate antibodies for targets selected by Synthon in support of the company\'s development of antibody-drug conjugates (ADCs) and alternative antibody-based therapeutics. MAB Discovery will employ its in vivo antibody discovery technology platform, which relies on the natural immune response of rabbits followed by state-of-the-art B-cell cloning techniques. Using a novel high-throughput screening route, MAB Discovery focuses on identifying highly active antibodies with unprecedented epitope coverage, potency and species cross-reactivity which has been successful for intractable targets. This technology eliminates affinity maturation and surrogate development which are very time-consuming and often sacrifice function. Synthon will obtain high quality antibodies in support of their strategy to create a portfolio of best-in-class antibody-based therapeutics, including ADCs. Additional details of the transaction were not disclosed.
Financial terms:
Latest news:
